WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES THERAPIX BIOSCIENCES LTD.Warrant Agreement • May 19th, 2020 • Therapix Biosciences Ltd. • Pharmaceutical preparations
THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, Capital Point Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 15, 2021 (the “Initial Exercise Date”) and on or prior to 4 p.m. on May 15, 2022 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Therapix Biosciences Ltd., a company organized under the laws of the State of Israel (the “Company”), up to the amount of Ordinary Shares of the Company (the “Warrant Shares”), to be represented by American Depositary Shares (“ADSs”), as subject to certain adjustment hereunder, and the ADSs issuable upon exercise of this Warrant (the “Warrant ADSs”). The aggregate value of ADSs purchasable under this Warrant shall not exceed $ 340,000. The number of Warrant ADSs underlying this Warrant shall be calculated acc
SHARE TRANSFER AGREEMENTShare Transfer Agreement • May 19th, 2020 • Therapix Biosciences Ltd. • Pharmaceutical preparations
THIS SHARE TRANSFER AGREEMENT (the “Agreement”) is made and entered into as of May 15, 2020, by and among, Capital Point Ltd., a public company traded on TASE, registered under the laws of the State of Israel and a shareholder of the Company (the “Seller”), Therapix Biosciences, Ltd., a public company traded on NASDAQ and registered under the laws of the State of Israel (“Therapix”) and Evero Health Ltd. a limited liability company, registered under the laws of the State of Israel and a wholly-owned subsidiary of Therapix (“Evero”). The Seller, Therapix and Evero are referred to herein from time to time as a “Party” or “party” and collectively as the “Parties” or “parties.”
ASSET TRANSFER AGREEMENTAsset Transfer Agreement • May 19th, 2020 • Therapix Biosciences Ltd. • Pharmaceutical preparations
This Asset Transfer Agreement (this “Agreement”) is dated as of May 17, 2020 by and between Therapix Biosciences Ltd., a public company traded on Nasdaq and registered under the laws of the State of Israel (“Transferor”) and Evero Health Ltd. a limited liability company, registered under the laws of the State of Israel and a wholly-owned subsidiary of the Transferor (“Transferee”) (Transferor and Transferee shall sometimes be referred to collectively as the “Parties”, and severally as a “Party”).
